Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
复制标题
DOI：
10.3960/jslrt.21003
复制
发表时间：
2021-12-22
期刊：
影响因子：
--
通讯作者：
Asano N
中科院分区：
文献类型：
--
作者：
Sakakibara A;Kohno K;Ishikawa E;Suzuki Y;Tsuyuki Y;Shimada S;Shimada K;Satou A;Takahara T;Ohashi A;Takahashi E;Kato S;Nakamura S;Asano N
程序性细胞死亡1 (PD1)/PD1配体（PD-L1）轴在肿瘤细胞逃避免疫控制中起重要作用，并已被广泛研究用于治疗目的。然而，PD-L1免疫组织化学仍未广泛用于诊断。我们回顾了PD-L1（通过克隆SP142）免疫组织化学在大细胞淋巴瘤中的诊断应用，主要包括经典霍奇金淋巴瘤（CHL）和弥漫性大b细胞淋巴瘤（DLBCL）。肿瘤性PD-L1 （nPD-L1）在霍奇金细胞和Reed-Sternberg细胞中的表达在原型CHL中得到了证实。值得注意的是，EBV+ CHL经常给与EBV+非恶性大b细胞外周t细胞淋巴瘤的鉴别诊断带来挑战；它们的区别是基于后者在大b细胞上缺乏PD-L1表达。nPD-L1的表达进一步为CHL合并原发性结外疾病提供了良好的诊断共识，该疾病可能具有肿瘤细胞免疫逃逸和免疫缺陷的联合发病机制。与CHL相比，nlpd - l1在DLBCL中的表达率要低得多，突出了血管内大b细胞淋巴瘤、原发性纵隔大b细胞淋巴瘤和EBV+ DLBCL的一些特异性亚群。它们由npd - l1阳性和阴性亚组组成，但其临床病理意义仍有待阐明。免疫细胞微环境PD-L1阳性可能与结外DLBCL的良好预后有关。PD-L1（通过SP142）免疫组化有助于我们了解可能与免疫逃逸和/或免疫缺陷相关的淋巴样肿瘤的免疫生物学。然而，对这些问题的了解仍然有限，应该在未来澄清诊断共识。
The programmed cell death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in tumor cell escape from immune control and has been most extensively investigated for therapeutic purposes. However, PD-L1 immunohistochemistry is still not used widely for diagnosis. We review the diagnostic utility of PD-L1 (by clone SP142) immunohistochemistry in large-cell lymphomas, mainly consisting of classic Hodgkin lymphoma (CHL) and diffuse large B-cell lymphoma (DLBCL). Neoplastic PD-L1 (nPD-L1) expression on Hodgkin and Reed-Sternberg cells is well-established among prototypic CHL. Of note, EBV+ CHL often poses a challenge for differential diagnosis from peripheral T-cell lymphoma with EBV+ non-malignant large B-cells; their distinction is based on the lack of PD-L1 expression on large B-cells in the latter. The nPD-L1 expression further provides a good diagnostic consensus for CHL with primary extranodal disease conceivably characterized by a combined pathogenesis of immune escape of tumor cells and immunodeficiency. Compared with CHL, the nPD-L1 expression rate is much lower in DLBCL, highlighting some specific subgroups of intravascular large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and EBV+ DLBCL. They consist of nPD-L1-positive and -negative subgroups, but their clinicopathological significance remains to be elucidated. Microenvironmental PD-L1 positivity on immune cells may be associated with a favorable prognosis in extranodal DLBCL. PD-L1 (by SP142) immunohistochemistry has helped us to understand the immune biology of lymphoid neoplasms possibly related by immune escape and/or immunodeficiency. However, knowledge of these issues remains limited and should be clarified for diagnostic consensus in the future.
登录
查看更多内容
原发性肠道弥漫性大 B 细胞淋巴瘤的临床病理学分析：CD5、PD-L1 和 Epstein-Barr 病毒对肿瘤细胞的预后评估。
影响因子：
4
作者：
Ishikawa E;Kato S;Shimada K;Tanaka T;Suzuki Y;Satou A;Kohno K;Sakakibara A;Yamamura T;Nakamura M;Miyahara R;Goto H;Nakamura S;Hirooka Y
通讯作者：
Hirooka Y
日本和美国血液学恶性肿瘤的发病率和趋势差异。
影响因子：
6.5
作者：
Chihara D;Ito H;Matsuda T;Shibata A;Katsumi A;Nakamura S;Tomotaka S;Morton LM;Weisenburger DD;Matsuo K
通讯作者：
Matsuo K
影响因子：
20.3
作者：
Green, Michael R.;Monti, Stefano;Shipp, Margaret A.
通讯作者：
Shipp, Margaret A.
影响因子：
6.3
作者：
Ishikawa, Eri;Nakamura, Masanao;Fujishiro, Mitsuhiro
通讯作者：
Fujishiro, Mitsuhiro
影响因子：
20.3
作者：
Carbone, Antonino;Gloghini, Annunziata;Carlo-Stella, Carmelo
通讯作者：
Carlo-Stella, Carmelo